Cancer

Cover image for Vol. 123 Issue 16

Early View (Online Version of Record published before inclusion in an issue)

Edited By: Fadlo R. Khuri, MD

Impact Factor: 5.997

ISI Journal Citation Reports © Ranking: 2016: 35/217 (Oncology)

Online ISSN: 1097-0142

Associated Title(s): Cancer Cytopathology, CA: A Cancer Journal for Clinicians

VIEW

  1. 1 - 100
  2. 101 - 152
  1. Original Articles

    1. Discipline

      Safety and Quality
      Preventable and mitigable adverse events in cancer care: Measuring risk and harm across the continuum

      Allison Lipitz-Snyderman, David Pfister, David Classen, Coral L. Atoria, Aileen Killen, Andrew S. Epstein, Christopher Anderson, Elizabeth Fortier and Saul N. Weingart

      Version of Record online: 17 AUG 2017 | DOI: 10.1002/cncr.30916

      This study assesses the nature and extent of adverse events among cancer patients across inpatient and outpatient settings. A heavy burden of adverse events is identified, and this highlights opportunities for oncology clinicians to think more broadly about oncology-related harm.

    2. Disease Site

      Hematologic Malignancies
      A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma

      Jatin J. Shah, Jonathan L. Kaufman, Jeffrey A. Zonder, Adam D. Cohen, William I. Bensinger, Brandi W. Hilder, Selena A. Rush, Duncan H. Walker, Brian J. Tunquist, Kevin S. Litwiler, Mieke Ptaszynski, Robert Z. Orlowski and Sagar Lonial

      Version of Record online: 17 AUG 2017 | DOI: 10.1002/cncr.30892

      • image
      • image
      • image
      • image

      Filanesib is a novel therapy which targets proliferation of malignant plasma cells. This study evaluates the appropriate dosing of filanesib as a single agent and in combination with dexamethasone for patients with relapsed/refractory multiple myeloma.

    3. Discipline

      Medical Oncology
      Drug development for breast, colorectal, and non-small cell lung cancers from 1979 to 2014

      Nancy A. Nixon, Omar F. Khan, Hasiba Imam, Patricia A. Tang, Jose Monzon, Haocheng Li, Gavin Sun, Doreen Ezeife, Sunil Parimi, Scot Dowden and Vincent C. Tam

      Version of Record online: 17 AUG 2017 | DOI: 10.1002/cncr.30919

      • image
      • image
      • image

      There is a high rate of attrition for oncology drugs entering clinical trials, and drugs are more likely to fail in later-stage clinical trials. The refinement of early-phase trial design may permit the selection of drugs that are more likely to succeed in the phase 3 setting.

    4. Outcomes Research
      Centralized patient-reported outcome data collection in transplantation is feasible and clinically meaningful

      Bronwen E. Shaw, Ruta Brazauskas, Heather R. Millard, Rachel Fonstad, Kathryn E. Flynn, Amy Abernethy, Jenny Vogel, Charney Petroske, Deborah Mattila, Rebecca Drexler, Stephanie J. Lee, Mary M. Horowitz and J. Douglas Rizzo

      Version of Record online: 17 AUG 2017 | DOI: 10.1002/cncr.30936

      • image

      Centralized patient-reported outcome data collection is feasible. Pretransplant patient-reported outcome scores predict 1-year survival.

  2. Commentary

    1. Setting the stage for universal financial distress screening in routine cancer care

      Nandita Khera, Jimmie C. Holland and Joan M. Griffin

      Version of Record online: 17 AUG 2017 | DOI: 10.1002/cncr.30940

      There is need to integrate financial burden assessment and management into routine cancer care delivery. Universal financial distress screening will allow for cost of care discussions to occur without embarrassment or fear between the patient, family, and treatment team during routine clinical care.

  3. Original Articles

    1. Disease Site

      Head and Neck Disease
      Combined high-intensity local treatment and systemic therapy in metastatic head and neck squamous cell carcinoma: An analysis of the National Cancer Data Base

      Zachary S. Zumsteg, Michael Luu, Emi J. Yoshida, Sungjin Kim, Mourad Tighiouart, John M. David, Stephen L. Shiao, Alain C. Mita, Kevin S. Scher, Eric J. Sherman, Nancy Y. Lee and Allen S. Ho

      Version of Record online: 17 AUG 2017 | DOI: 10.1002/cncr.30933

      • image
      • image
      • image
      • image

      High-intensity local treatment, consisting of radiation doses of at least 60 Gy or oncologic surgery, is associated with improved survival for patients presenting with metastatic head and neck cancer and undergoing systemic therapy in comparison with lower intensity or no local treatment. This effect persists in propensity score–matched cohorts, in landmark analyses, and with adjustments for the number and location of metastatic sites.

    2. Discipline

      Medical Oncology
      Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis

      Mohamad Bassam Sonbol, Belal Firwana, Zhen Wang, Diana Almader-Douglas, Mitesh J. Borad, Issam Makhoul, Ramesh K. Ramanathan, Daniel H. Ahn and Tanios Bekaii-Saab

      Version of Record online: 17 AUG 2017 | DOI: 10.1002/cncr.30927

      • image
      • image
      • image

      The combination of oxaliplatin with various irinotecan formulations results in improved progression-free survival over single-agent fluoropyrimidines. Although the combination of fluoropyrimidine with an irinotecan formulation produces an overall survival advantage, oxaliplatin with fluoropyrimidine after gemcitabine failure will need further confirmatory studies. Until then, the combination of fluoropyrimidine with irinotecan formulations, specifically 5-fluorouracil/nanoliposomal irinotecan, with the phase 3 evidence, appears to be the appropriate next line of treatment upon progression after gemcitabine-based chemotherapy regimens.

    3. Disease Site

      Endocrine Disease
      Changes in standardized mortality rates from thyroid cancer in Korea between 1985 and 2015: Analysis of Korean national data

      Yun Mi Choi, Won Gu Kim, Hyemi Kwon, Min Ji Jeon, Minkyu Han, Tae Yong Kim, Young Kee Shong, Sang Mo Hong, Eun-Gyoung Hong and Won Bae Kim

      Version of Record online: 17 AUG 2017 | DOI: 10.1002/cncr.30943

      • image
      • image

      Thyroid cancer mortality in Korea increased until 2003-2004 and then started to decrease, both in men and women. The increase in the early diagnosis of thyroid cancer, changes in exposure to risk factors, and standardization in diagnosis and treatment might be associated with the decrease in thyroid cancer mortality in Korea.

    4. Breast Disease
      The association between patient attitudes and values and the strength of consideration for contralateral prophylactic mastectomy in a population-based sample of breast cancer patients

      Sarah T. Hawley, Kent A. Griffith, Ann S. Hamilton, Kevin C. Ward, Monica Morrow, Nancy K. Janz, Steven J. Katz and Reshma Jagsi

      Version of Record online: 15 AUG 2017 | DOI: 10.1002/cncr.30924

      • image
      • image

      Many breast cancer patients consider contralateral prophylactic mastectomy, and their consideration is related to their decision styles and values. Understanding these styles and values could provide an opportunity for improving patient-clinician discussions about breast cancer treatment.

    5. Genitourinary Disease
      Advances in the diagnosis of hereditary kidney cancer: Initial results of a multigene panel test

      Kevin A. Nguyen, Jamil S. Syed, Carin R. Espenschied, Holly LaDuca, Ansh M. Bhagat, Alfredo Suarez-Sarmiento, Timothy K. O'Rourke Jr, Karina L. Brierley, Erin W. Hofstatter and Brian Shuch

      Version of Record online: 8 AUG 2017 | DOI: 10.1002/cncr.30893

      • image
      • image

      Panel tests may be particularly useful for patients who lack distinguishing clinical characteristics of known hereditary kidney cancer syndromes. The current results support the use of age at onset to determine whether genetic counseling and/or testing are appropriate, because such hereditary syndromes are associated with an earlier age of cancer onset.

    6. Discipline

      Clinical Trials
      Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590)

      Aarti K. Bhatia, Ju-Whei Lee, Harlan A. Pinto, Charlotte D. Jacobs, Paul J. Limburg, Philip Rubin, Robert M. Arusell, Eamonn P. Dunphy, Janardan D. Khandekar, Seth A. Reiner, Luis Baez-Diaz, Paul Celano, Shuli Li, Yi Li, Barbara A. Burtness, George L. Adams and Kishan J. Pandya

      Version of Record online: 7 AUG 2017 | DOI: 10.1002/cncr.30920

      • image
      • image

      Effective chemoprevention is an unmet need in head and neck cancers. This study reports on the lowest dose of retinoids ever studied for this indication and provides the longest follow-up to date.

    7. Survivorship
      Cancer survivorship and opioid prescribing rates: A population-based matched cohort study among individuals with and without a history of cancer

      Rinku Sutradhar, Armend Lokku and Lisa Barbera

      Version of Record online: 7 AUG 2017 | DOI: 10.1002/cncr.30839

      • image

      Survivors of cancer have substantially higher opioid prescribing rates compared with matched controls without a history of cancer, and this association is seen even long after attaining survivorship. Individuals with lower levels of socioeconomic status who are younger, from rural neighborhoods, and have more comorbidity have significantly higher prescribing rates.

    8. Clinical Trials
      Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas

      Michael Wahl, Susan M. Chang, Joanna J. Phillips, Annette M. Molinaro, Joseph F. Costello, Tali Mazor, Sanda Alexandrescu, Janine M. Lupo, Sarah J. Nelson, Mitchel Berger, Michael Prados, Jennie W. Taylor, Nicholas Butowski, Jennifer L. Clarke and Daphne Haas-Kogan

      Version of Record online: 31 JUL 2017 | DOI: 10.1002/cncr.30909

      • image
      • image

      The inhibition of mammalian target of rapamycin with everolimus has yielded a high rate of clinical stability in a phase 2 clinical trial of patients with recurrent low-grade gliomas. Activation of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway appears to be an important molecular prognostic marker of clinical outcomes.

    9. Feasibility and preliminary effects of resistance training and nutritional supplements during versus after radiotherapy in patients with head and neck cancer: A pilot randomized trial

      Jon Arne Sandmæl, Asta Bye, Tora Skeidsvoll Solheim, Guro Birgitte Stene, Lene Thorsen, Stein Kaasa, Jo-Åsmund Lund and Line Merethe Oldervoll

      Version of Record online: 31 JUL 2017 | DOI: 10.1002/cncr.30901

      • image

      The results of the current randomized pilot trial indicate that an exercise and nutrition intervention is feasible for patients with head and neck cancer during radiotherapy. Such an intervention may contribute toward mitigating loss of muscle mass both during and after treatment.

  4. Review Articles

    1. A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials

      Amer M. Zeidan, Maximilian Stahl, Mikkael A. Sekeres, David P. Steensma, Rami S. Komrokji and Steven D. Gore

      Version of Record online: 31 JUL 2017 | DOI: 10.1002/cncr.30903

      • image
      • image
      • image

      Hypomethylating agents have galvanized drug development in patients with myelodysplastic syndromes, but their effect on overall survival is controversial. Patients with high-risk myelodysplastic syndromes should be included in clinical trials as early as possible rather than after failure of therapy with hypomethylating agents.

  5. Original Articles

    1. Disease Site

      Gastrointestinal Disease
      Health care disparities among octogenarians and nonagenarians with stage II and III rectal cancer

      Richard J. Cassidy, Jeffrey M. Switchenko, En Cheng, Renjian Jiang, Jaymin Jhaveri, Kirtesh R. Patel, Daniel G. Tanenbaum, Maria C. Russell, Conor E. Steuer, Theresa W. Gillespie, Mark W. McDonald and Jerome C. Landry

      Version of Record online: 31 JUL 2017 | DOI: 10.1002/cncr.30896

      • image
      • image

      Octogenarians and nonagenarians with stage II/III rectal adenocarcinomas are underrepresented in the clinical trials establishing preoperative chemoradiation and then resection as the standard of care. In this analysis of the National Cancer Data Base of patients who are 80 years old or older and have stage II/III rectal cancer, the receipt of chemoradiation followed by surgery improves overall survival, and this is confirmed by multivariate analysis, interaction effect testing, and propensity score–matched analysis. Almost 15% of these elderly patients do not receive any cancer-directed care, with African American race and living in a less educated census tract placing a patient at risk for not receiving care.

    2. Soft Tissue and Bone Sarcoma
      Nonrhabdomyosarcoma soft tissue sarcoma (NRSTS) in pediatric and young adult patients: Results from a prospective study using limited-margin radiotherapy

      Christopher L. Tinkle, Israel Fernandez-Pineda, April Sykes, Zhaohua Lu, Chia-ho Hua, Michael D. Neel, Armita Bahrami, Barry L. Shulkin, Sue C. Kaste, Alberto Pappo, Sheri L. Spunt and Matthew J. Krasin

      Version of Record online: 31 JUL 2017 | DOI: 10.1002/cncr.30793

      • image
      • image
      • image

      Long-term results of a prospective phase 2 clinical trial using limited-margin radiotherapy for young patients with high-grade nonrhabdomyosarcoma soft tissue sarcoma reveal excellent local control without excess marginal failure and acceptable morbidity. These results validate ongoing national cooperative efforts to institute significant reductions in target volumes and normal tissue exposure with radiotherapy for this vulnerable population.

    3. Discipline

      Epidemiology
      Contribution of solid organ transplant recipients to the pediatric non-hodgkin lymphoma burden in the United States

      Elizabeth L. Yanik, Meredith S. Shiels, Jodi M. Smith, Christina A. Clarke, Charles F. Lynch, Amy R. Kahn, Lori Koch, Karen S. Pawlish and Eric A. Engels

      Version of Record online: 31 JUL 2017 | DOI: 10.1002/cncr.30923

      • image

      Transplant recipients contribute 2.82% of all pediatric non-Hodgkin lymphoma diagnoses and 7.62% of all pediatric diffuse large B cell lymphoma diagnoses. Prevention efforts targeted toward solid organ transplant recipients could measurably reduce the overall burden of pediatric non-Hodgkin lymphoma, particularly diffuse large B cell lymphoma.

    4. Outcomes Research
      A centralized mailed program with stepped increases of support increases time in compliance with colorectal cancer screening guidelines over 5 years: A randomized trial

      Beverly B. Green, Melissa L. Anderson, Andrea J. Cook, Jessica Chubak, Sharon Fuller, Richard T. Meenan and Sally W. Vernon

      Version of Record online: 28 JUL 2017 | DOI: 10.1002/cncr.30908

      • image
      • image

      In a health care organization with clinic-based activities to increase colorectal cancer screening, adding a centralized screening program has led to significant increases in colorectal cancer screening adherence over 5 years and to fewer individuals with no colorectal cancer screening.

    5. Disease Site

      Hematologic Malignancies
      C-MYC–positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional “hits” and outcomes with subsequent therapy

      Narendranath Epperla, Kami J. Maddocks, Mohammed Salhab, Julio C. Chavez, Nishitha Reddy, Reem Karmali, Elvira Umyarova, Veronika Bachanova, Cristiana Costa, Martha Glenn, Oscar Calzada, Ana C. Xavier, Zheng Zhou, Nasheed M. Hossain, Francisco J. Hernandez-Ilizaliturri, Zeina Al-Mansour, Stefan K. Barta, Saurabh Chhabra, Frederick Lansigan, Amitkumar Mehta, Michael V. Jaglal, Andrew Evans, Christopher R. Flowers, Jonathon B. Cohen, Timothy S. Fenske, Mehdi Hamadani and Luciano J. Costa

      Version of Record online: 27 JUL 2017 | DOI: 10.1002/cncr.30895

      • image
      • image

      The impact of MYC translocations (with or without additional BCL2 or BCL6 gene rearrangements) on response to salvage therapy and survival in patients with diffuse large B-cell lymphoma who experience primary treatment failure is not well defined. In this retrospective study, patients with MYC-positive DLBCL who fail on primary treatment have response rates similar to those observed after salvage therapy compared with their MYC-negative counterparts, but their survival is dismal irrespective of additional “hits” and hematopoietic cell transplantation, representing an unmet medical need.

    6. Genitourinary Disease
      The lack of a relationship between physician payments from drug manufacturers and Medicare claims for abiraterone and enzalutamide

      Jathin Bandari, Omar M. Ayyash, Robert M. Turner II, Bruce L. Jacobs and Benjamin J. Davies

      Version of Record online: 27 JUL 2017 | DOI: 10.1002/cncr.30914

      • image
      • image
      • image

      The results of the current study demonstrate that no difference in prescription count exists between prescribers who receive industry payments and those who do not for abiraterone and enzalutamide. At the outliers there may be an association between payments and prescription patterns.

    7. Discipline

      Bioethics and Legal Oncology
      Cancer donor preferences for disposition of their biospecimens after biobank closure

      Samuel C. Allen, Margie D. Dixon, Jeffrey M. Switchenko and Rebecca D. Pentz

      Version of Record online: 26 JUL 2017 | DOI: 10.1002/cncr.30910

      At the time of biobank closure, oncology biospecimen donors prefer that their biospecimens be transferred to an academic or national biobank and not to a for-profit biobank or one located outside of the United States. These data can inform educational initiatives and the policies of biobanks that serve oncology investigators.

    8. Disease Site

      Hematologic Malignancies
      Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis

      Judith Neukirchen, Michael Lauseker, Barbara Hildebrandt, Ann-Christin Nolting, Jennifer Kaivers, Guido Kobbe, Norbert Gattermann, Rainer Haas and Ulrich Germing

      Version of Record online: 26 JUL 2017 | DOI: 10.1002/cncr.30917

      • image
      • image
      • image
      • image
      • image

      Cytogenetic clonal evolution is associated with shorter survival and higher acute myeloid leukemia transformation rates. The presence of subclones indicates a more aggressive phenotype of myelodysplastic syndromes with an adverse prognosis.

  6. Erratum

    1. You have free access to this content
      Erratum

      Version of Record online: 25 JUL 2017 | DOI: 10.1002/cncr.30890

      This article corrects:

      Colorectal cancer screening: Estimated future colonoscopy need and current volume and capacity

      Vol. 122, Issue 16, 2479–2486, Version of Record online: 20 MAY 2016

    2. You have free access to this content
      Erratum

      Version of Record online: 25 JUL 2017 | DOI: 10.1002/cncr.30891

      This article corrects:
    3. You have free access to this content
      Erratum

      Version of Record online: 25 JUL 2017 | DOI: 10.1002/cncr.30889

      This article corrects:

      The promise of molecular staging for the future

      Vol. 123, Issue 5, 728–730, Version of Record online: 6 JAN 2017

  7. Original Articles

    1. Disease Site

      Genitourinary Disease
      Current trends in patient enrollment for robotic-assisted laparoscopic prostatectomy in Belgium

      Simone Albisinni, Steven Joniau, Thierry Quackels, Greet De Coster, Peter Dekuyper, Ben Van Cleynenbreugel, Nancy Van Damme, Elisabeth Van Eycken, Filip Ameye, Thierry Roumeguère and Be-RALP Registry (Belgian Robotic-Assisted Laparoscopic Prostatectomy Registry)

      Version of Record online: 25 JUL 2017 | DOI: 10.1002/cncr.30874

      • image
      • image

      During the last decade, an inverse stage migration has been observed in radical prostatectomy series at tertiary centers. The current study confirms this trend in robotic prostatectomy in Belgium, with patients with more aggressive cancers being enrolled for radical robotic surgery.

    2. Chest and Lung Disease
      HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium

      Rathi N. Pillai, Madhusmita Behera, Lynne D. Berry, Mike R. Rossi, Mark G. Kris, Bruce E. Johnson, Paul A. Bunn, Suresh S. Ramalingam and Fadlo R. Khuri

      Version of Record online: 25 JUL 2017 | DOI: 10.1002/cncr.30869

      • image

      In the current study, human epidermal growth factor receptor 2 (HER2) mutations are reported in 3% of patients with lung adenocarcinoma in the Lung Cancer Mutation Consortium. The survival of this subgroup of patients appears to be similar regardless of whether they received HER2-targeted therapy, but further investigation of HER2-targeted therapies may help to improve outcomes.

    3. Hematologic Malignancies
      Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients

      Preetesh Jain, Hagop M. Kantarjian, Ahmad Ghorab, Koji Sasaki, Elias J. Jabbour, Graciela Nogueras Gonzalez, Rashmi Kanagal-Shamanna, Ghayas C. Issa, Guillermo Garcia-Manero, Devendra KC, Sara Dellasala, Sherry Pierce, Marina Konopleva, William G. Wierda, Srdan Verstovsek, Naval G. Daver, Tapan M. Kadia, Gautam Borthakur, Susan O'Brien, Zeev Estrov, Farhad Ravandi and Jorge E. Cortes

      Version of Record online: 25 JUL 2017 | DOI: 10.1002/cncr.30864

      • image
      • image
      • image

      In the current study, myeloid immunophenotype, prior treatment with tyrosine kinase inhibitors (TKIs), older age, higher lactate dehydrogenase level, low platelet count, stem cell transplantation after blast phase (BP) diagnosis, chronic myeloid leukemia (CML) transformed from chronic phase/accelerated phase, and the presence of chromosome 15 abnormalities are found to be predictive of poor survival in patients with CML-BP. Patients with CML-BP who are treated with a combination of a TKI with chemotherapy appear to have superior survival compared with patients treated with a TKI alone.

    4. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia

      Laurence Legros, Franck E. Nicolini, Gabriel Etienne, Philippe Rousselot, Delphine Rea, Stéphane Giraudier, Agnès Guerci-Bresler, Françoise Huguet, Martine Gardembas, Martine Escoffre, Jean-Christophe Ianotto, Marie-Pierre Noël, Bruno R. Varet, Thomas Pagliardini, Irit Touitou, Stéphane Morisset, Francois-Xavier Mahon and on behalf of the French Intergroup for Chronic Myeloid Leukemias

      Version of Record online: 25 JUL 2017 | DOI: 10.1002/cncr.30885

      • image
      • image
      • image
      • image

      RE-STIM is a French observational, multicenter study evaluating treatment-free remission in 70 patients who re-attempt tyrosine kinase inhibitor discontinuation after a first unsuccessful attempt, with the loss of a major molecular response used as a trigger for therapy re-introduction. No safety issue is reported, and the treatment-free remission rate at 36 months is 34% (95% confidence interval, 23.6%-49%), demonstrating that a first failed attempt at discontinuing tyrosine kinase inhibitor does not preclude a second successful attempt.

    5. Discipline

      Survivorship
      Chronic hepatitis C virus infection and neurocognitive function in adult survivors of childhood cancer

      Adrienne Studaway, Rohit P. Ojha, Tara M. Brinkman, Nan Zhang, Malek Baassiri, Pia Banerjee, Matthew J. Ehrhardt, Deokumar Srivastava, Leslie L. Robison, Melissa M. Hudson and Kevin R. Krull

      Version of Record online: 25 JUL 2017 | DOI: 10.1002/cncr.30913

      Hepatitis C virus–seropositive survivors demonstrate poorer neurocognitive function and health-related quality-of-life than hepatitis C virus–seronegative survivors. The diagnosis of liver cirrhosis does not account for the poorer neurocognitive function observed in this cohort.

    6. Disease Site

      Genitourinary Disease
      Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology

      Malte W. Vetterlein, Stephanie A. M. Wankowicz, Thomas Seisen, Richard Lander, Björn Löppenberg, Felix K.-H. Chun, Mani Menon, Maxine Sun, Justine A. Barletta, Toni K. Choueiri, Joaquim Bellmunt, Quoc-Dien Trinh and Mark A. Preston

      Version of Record online: 25 JUL 2017 | DOI: 10.1002/cncr.30907

      • image
      • image

      When evaluating the impact of neoadjuvant chemotherapy before radical cystectomy for patients with nonpure urothelial histological variants, only those patients with neuroendocrine tumors appear to experience an overall survival benefit. Patients with micropapillary differentiation, sarcomatoid urothelial tumors, and adenocarcinoma who receive neoadjuvant chemotherapy are less likely to harbor non-organ-confined disease at the time of radical cystectomy, but do not appear to have an increased rate of overall survival.

    7. Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer

      David B. Cahn, Elizabeth A. Handorf, Eric M. Ghiraldi, Benjamin T. Ristau, Daniel M. Geynisman, Thomas M. Churilla, Eric M. Horwitz, Mark L. Sobczak, David Y.T. Chen, Rosalia Viterbo, Richard E. Greenberg, Alexander Kutikov, Robert G. Uzzo and Marc C. Smaldone

      Version of Record online: 25 JUL 2017 | DOI: 10.1002/cncr.30900

      • image
      • image
      • image

      In the National Cancer Data Base, the receipt of bladder-preservation therapy appears to be associated with decreased overall survival compared with treatment with radical cystectomy in all patients with stage II to III urothelial carcinoma of the bladder. The use of increasingly stringent definitions of bladder-preservation therapy along with more rigorous statistical methods attenuates the observed overall survival differences.

    8. Discipline

      Epidemiology
      Adolescent body mass index and risk of colon and rectal cancer in a cohort of 1.79 million Israeli men and women: A population-based study

      Zohar Levi, Jeremy D. Kark, Lior H. Katz, Gilad Twig, Estela Derazne, Dorit Tzur, Yaara Leibovici Weissman, Adi Leiba, Irena Lipshiez, Lital Keinan Boker and Arnon Afek

      Version of Record online: 24 JUL 2017 | DOI: 10.1002/cncr.30819

      • image
      • image
      • image
      • image

      Being overweight and obese in adolescence is associated with an increased risk of subsequent colon cancer in men and women, whereas obesity is associated with rectal cancer.

    9. Disease Site

      Head and Neck Disease
      National evaluation of multidisciplinary quality metrics for head and neck cancer

      John D. Cramer, Sedona E. Speedy, Robert L. Ferris, Alfred W. Rademaker, Urjeet A. Patel and Sandeep Samant

      Version of Record online: 20 JUL 2017 | DOI: 10.1002/cncr.30902

      • image
      • image
      • image

      Five different quality metrics for surgically resected head and neck cancer are identified that are measurable in cancer registries, under the influence of care providers, have widespread variation, and impact survival. These quality metrics meet criteria for validity and are candidates for more widespread adoption.

    10. Discipline

      Disparities Research
      A multidimensional view of racial differences in access to prostate cancer care

      Craig Evan Pollack, Katrina A. Armstrong, Nandita Mitra, Xinwei Chen, Katelyn R. Ward, Archana Radhakrishnan, Michelle S. Wong, Justin E. Bekelman, Charles C. Branas, Karin V. Rhodes and David T. Grande

      Version of Record online: 20 JUL 2017 | DOI: 10.1002/cncr.30894

      • image

      The current study presents what to the authors' knowledge is the first comprehensive assessment of access to prostate cancer care. The authors report that although access appears to be positively correlated with a higher overall perceived quality of care and better physician-patient communication, it does not appear to explain observed racial differences.

    11. Supportive Care
      The role of medical/nursing skills training in caregiver confidence and burden: A CanCORS study

      Michelle A. Mollica, Kristin Litzelman, Julia H. Rowland and Erin E. Kent

      Version of Record online: 20 JUL 2017 | DOI: 10.1002/cncr.30875

      • image
      • image
      • image

      Informal cancer caregivers provide essential support to cancer patients, including the delivery of direct medical/nursing care, assistance with activities of daily living, and social support. Results indicate that training is a potential area for interventions to reduce the caregiver burden, but future research on how best to provide training for caregivers (ie, content, mode of delivery, and timing) is needed.

    12. Disease Site

      Hepatobiliary Disease
      Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review

      Susanna W. L. de Geus, Mariam F. Eskander, Gyulnara G. Kasumova, Sing Chau Ng, Tara S. Kent, Joseph D. Mancias, Mark P. Callery, Anand Mahadevan and Jennifer F. Tseng

      Version of Record online: 14 JUL 2017 | DOI: 10.1002/cncr.30856

      • image
      • image
      • image

      This population-level analysis demonstrates that stereotactic body radiotherapy is associated with a significantly better outcome than chemotherapy alone or in conjunction with traditional external-beam radiotherapy. These results emphasize that stereotactic body radiotherapy is a promising treatment approach for patients with unresected pancreatic cancer.

    13. Discipline

      Survivorship
      Effects of high-intensity aerobic interval training on cardiovascular disease risk in testicular cancer survivors: A phase 2 randomized controlled trial

      Scott C. Adams, Darren S. DeLorey, Margie H. Davenport, Michael K. Stickland, Adrian S. Fairey, Scott North, Alexander Szczotka and Kerry S. Courneya

      Version of Record online: 14 JUL 2017 | DOI: 10.1002/cncr.30859

      • image

      Overall survival from testicular cancer may be reduced by the development of treatment-related cardiovascular disease. To our knowledge, we report the first phase 2 randomized controlled trial to demonstrate that high-intensity aerobic interval training positively influences drivers of atherosclerotic cardiovascular disease and surrogate markers of cardiovascular and overall mortality in testicular cancer survivors.

    14. Disparities Research
      Colorectal cancer screening at US community health centers: Examination of sociodemographic disparities and association with patient-provider communication

      Sue C. Lin, Duane McKinley, Alek Sripipatana and Laura Makaroff

      Version of Record online: 14 JUL 2017 | DOI: 10.1002/cncr.30855

      • image

      The colorectal cancer screening rate for community health center patients is 57.9%, whereas the rate is 65.1% according to the 2012 Behavioral Risk Factor Surveillance System and 58.2% according to the 2013 National Health Interview Survey. Addressing the lack of insurance, making culturally and linguistically appropriate patient education materials available, and training clinicians and care teams in cultural competency are critical for increasing future colorectal cancer screening rates.

    15. Clinical Trials
      A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia

      Elias Jabbour, Nicholas J. Short, Farhad Ravandi, Xuelin Huang, Lianchun Xiao, Guillermo Garcia-Manero, William Plunkett, Varsha Gandhi, Koji Sasaki, Naveen Pemmaraju, Naval G. Daver, Gautam Borthakur, Nitin Jain, Marina Konopleva, Zeev Estrov, Tapan M. Kadia, William G. Wierda, Courtney D. DiNardo, Mark Brandt, Susan M. O'Brien, Jorge E. Cortes and Hagop Kantarjian

      Version of Record online: 14 JUL 2017 | DOI: 10.1002/cncr.30883

      • image
      • image
      • image

      Idarubicin and cytarabine with clofarabine and idarubicin and cytarabine with fludarabine have similar efficacy in younger patients with newly diagnosed acute myeloid leukemia, although the regimen of idarubicin and cytarabine with fludarabine is associated with a better toxicity profile. In patients aged <50 years, the addition of fludarabine to standard chemotherapy may improve survival.

    16. Epidemiology
      Malignant central nervous system tumors among adolescents and young adults (15-39 years old) in 14 Southern-Eastern European registries and the US Surveillance, Epidemiology, and End Results program: Mortality and survival patterns

      Marios K. Georgakis, Paraskevi Papathoma, Anton Ryzhov, Snezana Zivkovic-Perisic, Sultan Eser, Łukasz Taraszkiewicz, Mario Sekerija, Tina Žagar, Luis Antunes, Anna Zborovskaya, Joana Bastos, Margareta Florea, Daniela Coza, Anna Demetriou, Domenic Agius, Rajko M. Strahinja, Marios Themistocleous, Maria Tolia, Spyridon Tzanis, George A. Alexiou, Panagiotis G. Papanikolaou, Panagiotis Nomikos, Maria Kantzanou, Nick Dessypris, Apostolos Pourtsidis and Eleni T. Petridou

      Version of Record online: 14 JUL 2017 | DOI: 10.1002/cncr.30884

      • image
      • image

      Exploiting population-based data from 14 cancer registries in Southern-Eastern Europe (1990-2014), this study calculates mortality and survival rates for malignant central nervous system tumors in the distinct age group of adolescents and young adults (15-39 years old) and compares them with US Surveillance, Epidemiology, and End Results data (1990-2012). Despite the survival gains observed during the last decades, the considerable outcome disparities between the less affluent Southern-Eastern Europe region and the United States for adolescents and young adults with malignant central nervous system tumors point to health care delivery inequalities.

    17. Translational Research
      Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer

      Satoshi Okazaki, Marta Schirripa, Fotios Loupakis, Shu Cao, Wu Zhang, Dongyun Yang, Yan Ning, Martin D. Berger, Yuji Miyamoto, Mitsukuni Suenaga, Syma Iqubal, Afsaneh Barzi, Chiara Cremolini, Alfredo Falcone, Francesca Battaglin, Lisa Salvatore, Beatrice Borelli, Timothy G. Helentjaris and Heinz-Josef Lenz

      Version of Record online: 14 JUL 2017 | DOI: 10.1002/cncr.30880

      • image
      • image
      • image
      • image

      A tandem repeat variation near the HIC1 (hypermethylated in cancer) promoter is associated with progression-free survival in patients with metastatic colorectal cancer who receive oxaliplatin-based chemotherapy. This tandem repeat variation could be a predictive marker for oxaliplatin.

    18. Medical Oncology
      Comparative “nocebo effects” in older patients enrolled in cancer therapeutic trials: Observations from a 446-patient cohort

      Jared C. Foster, Jennifer G. Le-Rademacher, Josephine L. Feliciano, Ajeet Gajra, Drew K. Seisler, Ronald DeMatteo, Jacqueline M. Lafky, Arti Hurria, Hyman B. Muss, Harvey J. Cohen and Aminah Jatoi

      Version of Record online: 12 JUL 2017 | DOI: 10.1002/cncr.30867

      Nocebo effects are examined in older patients with cancer. On the basis of analyses of 2 large, prospectively conducted studies, adverse events are equally common in older and younger nocebo-exposed patients with cancer and thus require the same degree of clinical consideration regardless of patient age.

    19. Disease Site

      Genitourinary Disease
      Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer

      Ericka M. Ebot, Travis Gerke, David P. Labbé, Jennifer A. Sinnott, Giorgia Zadra, Jennifer R. Rider, Svitlana Tyekucheva, Kathryn M. Wilson, Rachel S. Kelly, Irene M. Shui, Massimo Loda, Philip W. Kantoff, Stephen Finn, Matthew G. Vander Heiden, Myles Brown, Edward L. Giovannucci and Lorelei A. Mucci

      Version of Record online: 12 JUL 2017 | DOI: 10.1002/cncr.30831

      • image
      • image

      Chromatin-related genes are expressed at higher levels in prostate tumors of obese men in comparison with healthy-weight men, and this expression is associated with worse outcomes. This provides biological support for obesity as a driver of aggressive disease and suggests further investigation of chromatin biomarkers.

    20. Discipline

      Disparities Research
      Disparities in location of death of adolescents and young adults with cancer: A longitudinal, population study in California

      Nitya Rajeshuni, Emily E. Johnston, Olga Saynina, Lee M. Sanders and Lisa J. Chamberlain

      Version of Record online: 12 JUL 2017 | DOI: 10.1002/cncr.30860

      • image
      • image

      The majority of adolescent and young adult cancer deaths in California occur in the hospital. Hospital death rates were found to be stable for the last 16 years of the study period and hospital deaths were more likely to take place for minority patients, younger patients, and those diagnosed with leukemia or lymphoma.

    21. Pediatric Oncology
      Immunogenicity and safety of single-dose, 13-valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patients

      Te-Yu Hung, Rishi S. Kotecha, Christopher C. Blyth, Sarah K. Steed, Ruth B. Thornton, Anne L. Ryan, Catherine H. Cole and Peter C. Richmond

      Version of Record online: 11 JUL 2017 | DOI: 10.1002/cncr.30764

      • image
      • image
      • image

      Children who receive immunosuppressive treatment for cancer are at high risk for invasive pneumococcal disease. The current study demonstrates that a single-dose, 13-valent pneumococcal conjugate vaccine is safe and immunogenic in children receiving therapy for cancer and that a dose should be received as soon as possible after diagnosis.

    22. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group

      Kevin Campbell, Julie M. Gastier-Foster, Meegan Mann, Arlene H. Naranjo, Collin Van Ryn, Rochelle Bagatell, Katherine K. Matthay, Wendy B. London, Meredith S. Irwin, Hiroyuki Shimada, M. Meaghan Granger, Michael D. Hogarty, Julie R. Park and Steven G. DuBois

      Version of Record online: 11 JUL 2017 | DOI: 10.1002/cncr.30873

      • image
      • image

      MYCN amplification is an established adverse prognostic factor in patients with neuroblastoma, although to the authors' knowledge little is known regarding patients with tumors with low-level copy number gain. Herein, the authors evaluate associations between MYCN copy number category and clinical features, biological features, and prognosis.

    23. Quality of Life
      You have full text access to this OnlineOpen article
      Empowerment in adolescents and young adults with cancer: Relationship with health-related quality of life

      Suzanne E.J. Kaal, Olga Husson, Saskia van Duivenboden, Rosemarie Jansen, Eveliene Manten-Horst, Petra Servaes, Judith B. Prins, Sanne W. van den Berg and Winette T.A. van der Graaf

      Version of Record online: 11 JUL 2017 | DOI: 10.1002/cncr.30827

      Empowerment is positively associated with health-related quality of life in adolescent and young adult patients with cancer. Interventions aiming at empowering these patients can improve their health-related quality of life.

    24. Epidemiology
      Cancer risk among Holocaust survivors in Israel—A nationwide study

      Siegal Sadetzki, Angela Chetrit, Laurence S. Freedman, Nina Hakak, Micha Barchana, Raphael Catane and Mordechai Shani

      Version of Record online: 10 JUL 2017 | DOI: 10.1002/cncr.30783

      On the basis of a nationwide cohort of Holocaust survivors who were exposed to various severe and protracted personal deprivations, cancer is diagnosed among 22.2% of survivors compared with 16% of a comparison group (P < .0001), and an excess risk is demonstrated for all cancer sites and for lung and colorectal cancers. The results add to the conflicting and sparse knowledge on this issue and support the notion that survivors of the Holocaust have a small but consistent increase in cancer risk. See also pages 000-000.

  8. Editorial

    1. Extreme population-level events: Do they have an impact on cancer?

      Beti Thompson, Sarah Gehlert and Electra D. Paskett

      Version of Record online: 10 JUL 2017 | DOI: 10.1002/cncr.30778

      The report by Sadetzki and colleagues in this issue showcases the impact of a horrendous event—the Holocaust—on subsequent health decades after the occurrence. Two additional calamities—country-wide famines and population-level discrimination—are provided as examples of this phenomenon to add evidence to the causal pathway identified by Sadetzki et al. See also pages 000-000.

  9. Original Articles

    1. Disease Site

      Neuro-Oncology
      The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: Results from a prospective clinical trial (CABARET)

      Kathryn M. Field, Pramit M. Phal, Greg Fitt, Christine Goh, Anna K. Nowak, Mark A. Rosenthal, John Simes, Elizabeth H. Barnes, Kate Sawkins, Lawrence M. Cher, Elizabeth J. Hovey and Helen Wheeler

      Version of Record online: 5 JUL 2017 | DOI: 10.1002/cncr.30838

      • image
      • image

      Data from a prospective, randomized phase 2 clinical trial of patients with recurrent glioblastoma have been used to determine whether the magnetic resonance imaging results at 4 weeks correlate with survival. Disease progression on early magnetic resonance imaging is strongly associated with inferior overall survival, and this is independent of other predictors of survival at the baseline.

    2. Discipline

      Quality of Life
      Longitudinal regret after treatment for low- and intermediate-risk prostate cancer

      Lauren M. Hurwitz, Jennifer Cullen, Daniel J. Kim, Sally Elsamanoudi, Jane Hudak, Maryellen Colston, Judith Travis, Huai-Ching Kuo, Kevin R. Rice, Christopher R. Porter and Inger L. Rosner

      Version of Record online: 5 JUL 2017 | DOI: 10.1002/cncr.30841

      • image
      • image

      Among low- and intermediate-risk prostate cancer patients receiving care at a multidisciplinary clinic, decisional regret is low 3 years after treatment. Decisional regret does not differ significantly between treatment groups but is greater in African American patients and in patients reporting poorer HRQoL.

    3. Radiation Oncology
      Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer

      Jean-Claude M. Rwigema, Vivek Verma, Liyong Lin, Abigail T. Berman, William P. Levin, Tracey L. Evans, Charu Aggarwal, Ramesh Rengan, Corey Langer, Roger B. Cohen and Charles B. Simone II

      Version of Record online: 5 JUL 2017 | DOI: 10.1002/cncr.30870

      • image
      • image

      This first ever prospective study evaluates the utility of concurrent chemotherapy and proton-beam radiation therapy for limited-stage small cell lung cancer. Proton-beam radiation therapy decreases cardiac and pulmonary doses (mean/volume receiving at least 5 Gy) in comparison with intensity-modulated radiotherapy and produces survival and toxicity outcomes that compare favorably with prior reports of conventional photon therapy.

  10. Review Articles

    1. Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: Myth or reality?

      Federica Tomao, Maurizio D'Incalci, Elena Biagioli, Fedro A. Peccatori and Nicoletta Colombo

      Version of Record online: 5 JUL 2017 | DOI: 10.1002/cncr.30830

      • image
      • image

      In this review, the authors analyze the hypothesis that platinum sensitivity might be restored through an extended platinum-free interval in patients with partially platinum-sensitive, recurrent ovarian cancer. Preclinical and clinical evidence is summarized.

  11. Original Articles

    1. Disease Site

      Head and Neck Disease
      Assessing the spectrum of germline variation in Fanconi anemia genes among patients with head and neck carcinoma before age 50

      Settara C. Chandrasekharappa, Steven B. Chinn, Frank X. Donovan, Naweed I. Chowdhury, Aparna Kamat, Adebowale A. Adeyemo, James W. Thomas, Meghana Vemulapalli, Caroline S. Hussey, Holly H. Reid, James C. Mullikin, Qingyi Wei and Erich M. Sturgis

      Version of Record online: 5 JUL 2017 | DOI: 10.1002/cncr.30802

      • image
      • image

      Patients with Fanconi anemia (FA) are at increased risk of head and neck squamous cell carcinoma (HNSCC), but the prevalence of undiagnosed FA in patients with HNSCC is unknown. Targeted germline sequencing of 417 patients with HNSCC identifies several known FA variant mutations and several novel FA mutations; FA mutations in HNSCC may explain a potential mechanism for tumorigenesis.

    2. Discipline

      Outcomes Research
      Establishing achievable benchmarks for quality improvement in systemic therapy for early-stage breast cancer

      Melanie Powis, Rinku Sutradhar, Alejandro Gonzalez, Katherine A. Enright, Nathan A. Taback, Christopher M. Booth, Maureen Trudeau and Monika K. Krzyzanowska

      Version of Record online: 5 JUL 2017 | DOI: 10.1002/cncr.30804

      • image
      • image

      Data-derived benchmarking can be used to facilitate quality improvement by defining an achievable target for which to strive. Benchmarking helps to identify areas of good performance as well as potential targets for quality improvement initiatives.

  12. Correspondence

    1. Reply to Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710

      Eric Ojerholm, Andrew Smith, Wei-Ting Hwang and John P. Christodouleas

      Version of Record online: 30 JUN 2017 | DOI: 10.1002/cncr.30871

  13. Original Articles

    1. Discipline

      Safety and Quality
      Understanding the relationship between the Centers for Medicare and Medicaid Services' Hospital Compare star rating, surgical case volume, and short-term outcomes after major cancer surgery

      Deborah R. Kaye, Edward C. Norton, Chad Ellimoottil, Zaojun Ye, James M. Dupree, Lindsey A. Herrel and David C. Miller

      Version of Record online: 30 JUN 2017 | DOI: 10.1002/cncr.30866

      • image
      • image
      • image

      Both the Centers for Medicare and Medicaid Services' Hospital Compare star rating and surgical case volume have been publicized as metrics that can help patients to identify high-quality hospitals for complex care such as cancer surgery. The current study evaluates the relationship between the Centers for Medicare and Medicaid Services' star rating, surgical volume, and short-term outcomes after major cancer surgery.

    2. Disease Site

      Endocrine Disease
      Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer

      Eric J. Sherman, Lara A. Dunn, Alan L. Ho, Shrujal S. Baxi, Ronald A. Ghossein, Matthew G. Fury, Sofia Haque, Cami S. Sima, Grace Cullen, James A. Fagin and David G. Pfister

      Version of Record online: 29 JUN 2017 | DOI: 10.1002/cncr.30861

      • image

      Sorafenib and temsirolimus appear to be an active combination in patients with radioactive-iodine refractory thyroid cancer, even in those who previously received sorafenib. This regimen also may have activity in anaplastic thyroid cancer.

    3. Hepatobiliary Disease
      Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma

      Neehar D. Parikh, Amit G. Singal and David W. Hutton

      Version of Record online: 29 JUN 2017 | DOI: 10.1002/cncr.30863

      • image
      • image
      • image

      Regorafenib confers a survival benefit as a second-line, systemic treatment for advanced hepatocellular carcinoma. The current study examines the cost effectiveness of regorafenib in this setting. See also pages 000-000.

    4. You have full text access to this OnlineOpen article
      Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials

      Goro Kasuya, Hirotoshi Kato, Shigeo Yasuda, Hiroshi Tsuji, Shigeru Yamada, Yasuo Haruyama, Gen Kobashi, Daniel K. Ebner, Naomi Nagatake Okada, Hirokazu Makishima, Masaru Miyazaki, Tadashi Kamada, Hirohiko Tsujii and for the Liver Cancer Working Group

      Version of Record online: 29 JUN 2017 | DOI: 10.1002/cncr.30816

      • image
      • image
      • image

      Sequential phase 1/2 and phase 2 prospective trials including 133 lesions in 124 patients with histologically proven hepatocellular carcinoma have been performed to evaluate the safety and efficacy of carbon-ion radiotherapy hypofractionation with 12, 8, and 4 fractions. Few severe adverse effects have been found, and the 3-year local-control rate is 91.4% for all lesions with a 3-year local-control rate of 95.5% in the phase 2 trial.

    5. Genome-wide association analysis identifies a GLUL haplotype for familial hepatitis B virus-related hepatocellular carcinoma

      You-Yu Lin, Ming-Whei Yu, Shi-Ming Lin, Shou-Dong Lee, Chih-Ling Chen, Ding-Shinn Chen and Pei-Jer Chen

      Version of Record online: 29 JUN 2017 | DOI: 10.1002/cncr.30851

      • image
      • image

      In the current study, genome-wide association analyses are performed to identify genetic factors associated with familial hepatitis B virus-related hepatocellular carcinoma. The results identify 2 familial hepatocellular carcinoma-specific susceptible haplotypes at glutamate-ammonia ligase (GLUL) and solute carrier family 13 member 2 (SLC13A2)/forkhead box N1 (FOXN1).

  14. Commentary

    1. Pembrolizumab as first-line therapy in programmed death ligand 1–positive advanced lung cancer: Is it as effective as we think it is?

      Daniel A. Goldstein, Usama Bilal and Vinay Prasad

      Version of Record online: 29 JUN 2017 | DOI: 10.1002/cncr.30868

      • image

      The KEYNOTE 024 trial compared the safety and efficacy of pembrolizumab versus chemotherapy in the first line setting of PD-L1 positive metastatic NSCLC and suggested an impressive survival benefit with pembrolizumab. The high level of censoring in the trial casts considerable uncertainty on the actual magnitude of the benefit provided with this treatment.

  15. Editorial

    1. At least, do no harm

      Harold O. Douglass Jr

      Version of Record online: 29 JUN 2017 | DOI: 10.1002/cncr.30865

      Are the physical and fiscal costs of a treatment really of value to the patient when the treatment provides only a chance for a small survival gain and a greater chance for patient discomfort? Physicians should remember the thrust of the Hippocratic Oath: “At least, do no harm.” See also pages 0000-0000.

  16. Original Articles

    1. Disease Site

      Genitourinary Disease
      Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system

      Ariel A. Schulman, Lauren E. Howard, Kae Jack Tay, Efrat Tsivian, Christina Sze, Christopher L. Amling, William J. Aronson, Matthew R. Cooperberg, Christopher J. Kane, Martha K. Terris, Stephen J. Freedland and Thomas J. Polascik

      Version of Record online: 29 JUN 2017 | DOI: 10.1002/cncr.30844

      • image
      • image

      The 2015 prostate cancer grade groups predict multiple long-term oncologic endpoints after radical prostatectomy in a racially mixed, equal-access health system. This system should be used for risk stratification and for counseling men with prostate cancer.

    2. Head and Neck Disease
      A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity

      Anne W. M. Lee, Stewart Y. Tung, Wai Tong Ng, Victor Lee, Roger K. C. Ngan, Horace C. W. Choi, Lucy L. K. Chan, Lillian L. Siu, Alice W. Y. Ng, To Wai Leung, Harry H. Y. Yiu, Brian O'Sullivan and Rick Chappell

      Version of Record online: 29 JUN 2017 | DOI: 10.1002/cncr.30850

      • image
      • image
      • image

      Compared with radiotherapy alone, concurrent chemotherapy and adjuvant chemotherapy could significantly improve overall survival for patients with regionally advanced nasopharyngeal carcinoma without an excessive increase in late toxicities.

    3. Discipline

      Survivorship
      Depressive symptoms predict cancer caregivers' physical health decline

      Kelly M. Shaffer, Youngmee Kim, Charles S. Carver and Rachel S. Cannady

      Version of Record online: 29 JUN 2017 | DOI: 10.1002/cncr.30835

      • image
      • image
      • image

      Latent growth modeling reveals that cancer caregivers' physical health declines from 2 to 8 years after the patients' diagnosis. Caregivers with high depressive symptoms at 2 years postdiagnosis report more pronounced physical health decline than other caregivers.

    4. Disease Site

      Genitourinary Disease
      Germline genetic variants in men with prostate cancer and one or more additional cancers

      Patrick G. Pilié, Anna M. Johnson, Kristen L. Hanson, Megan E. Dayno, Ashley L. Kapron, Elena M. Stoffel and Kathleen A. Cooney

      Version of Record online: 28 JUN 2017 | DOI: 10.1002/cncr.30817

      • image
      • image

      In the current study, pathogenic germline mutations in cancer-predisposing genes, predominantly involved in the DNA damage repair pathway, are found in a significant minority of a selected population of men with prostate cancer and at least 1 other primary malignancy. The majority of the men with germline mutations would not have qualified for clinical genetic testing under current guidelines, thereby highlighting the need for expanded inclusion criteria for genetic testing in patients with prostate cancer, particularly given the impact of pathogenic germline mutations on not only a proband's own treatment but also cancer screening and prevention strategies for his entire family.

    5. Discipline

      Outcomes Research
      Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database

      Stephen J. Freedland, Adriana C. Vidal, Lauren E. Howard, Martha K. Terris, Matthew R. Cooperberg, Christopher L. Amling, Christopher J. Kane, William J. Aronson and For the Shared Equal Access Regional Cancer Hospital (SEARCH) Database Study Group

      Version of Record online: 27 JUN 2017 | DOI: 10.1002/cncr.30834

      • image
      • image
      • image
      • image
      • image

      Among men undergoing radical prostatectomy at equal-access centers, although black men have an increased risk of biochemical disease recurrence, they appear to have risks of aggressive disease recurrence, metastasis, and prostate cancer-specific death similar to those of white men. The risk of biochemical disease recurrence is similar after controlling for risk parameters.

    6. Psychosocial Oncology
      The Hospital Anxiety and Depression Scale (HADS) and the 9-item Patient Health Questionnaire (PHQ-9) as screening instruments for depression in patients with cancer

      Tim J. Hartung, Michael Friedrich, Christoffer Johansen, Hans-Ulrich Wittchen, Herman Faller, Uwe Koch, Elmar Brähler, Martin Härter, Monika Keller, Holger Schulz, Karl Wegscheider, Joachim Weis and Anja Mehnert

      Version of Record online: 27 JUN 2017 | DOI: 10.1002/cncr.30846

      • image
      • image
      • image

      In patients with cancer, the screening performance of both the 9-item Patient Health Questionnaire depression module and the Hospital Anxiety and Depression Scale depression subscale is limited compared with a standardized diagnostic interview. Costs and benefits of routinely screening all patients with cancer should be weighed carefully.

    7. Survivorship
      Survivorship and the chronic cancer patient: Patterns in treatment-related effects, follow-up care, and use of survivorship care plans

      Melissa A. Frick, Carolyn C. Vachani, Christina Bach, Margaret K. Hampshire, Karen Arnold-Korzeniowski, James M. Metz and Christine E. Hill-Kayser

      Version of Record online: 27 JUN 2017 | DOI: 10.1002/cncr.30862

      Using data obtained from an Internet-based survivorship care plan tool, this study demonstrates that a substantial number of survivors living with chronic cancer, who are often considered incurable but treatable, seek survivorship information and support. These survivors face particular disparities in survivorship care in comparison with their counterparts treated with curative intent. These disparities include a greater burden of patient-reported treatment effects, reduced participation of primary care providers in the cancer care team, a lower proportion of health care providers generating survivorship care plans for follow-up care, and decreased satisfaction with currently available survivorship care plans.

    8. Disparities Research
      Race-specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patients

      Nicholas W. Bateman, Elizabeth A. Dubil, Guisong Wang, Brian L. Hood, Julie M. Oliver, Tracy A. Litzi, Glenn D. Gist, David A. Mitchell, Brian Blanton, Neil T. Phippen, Chunqiao Tian, Christopher M. Zahn, David E. Cohn, Laura J. Havrilesky, Andrew Berchuck, Craig D. Shriver, Kathleen M. Darcy, Chad A. Hamilton, Thomas P. Conrads and G. Larry Maxwell

      Version of Record online: 27 JUN 2017 | DOI: 10.1002/cncr.30813

      • image
      • image
      • image

      Disparities in disease outcomes between black and white patients with endometrial cancer may be due in part to inherent differences in the disease biology. This study has identified conserved molecular alterations between black and white patients with endometrioid endometrial cancer correlating with differential disease outcomes, and it provides further insights into the association of race-specific biology with disease prognosis in patients with endometrial cancer.

    9. Pediatric Oncology
      Young adult survivors of childhood acute lymphoblastic leukemia show evidence of chronic inflammation and cellular aging

      Hany Ariffin, Mohamad Shafiq Azanan, Sayyidatul Syahirah Abd Ghafar, Lixian Oh, Kee Hie Lau, Tharshanadhevasheri Thirunavakarasu, Atiqah Sedan, Kamariah Ibrahim, Adelyne Chan, Tong Foh Chin, Fong Fong Liew, Shareni Jeyamogan, Erda Syerena Rosli, Rashidah Baharudin, Tsiao Yi Yap, Roderick Skinner, Su Han Lum and Pierre Hainaut

      Version of Record online: 27 JUN 2017 | DOI: 10.1002/cncr.30857

      • image
      • image

      Compared with peers of the same age without cancer, young adult survivors of childhood leukemia have evidence of cellular aging that may predispose them to develop debilitating chronic conditions at earlier than expected ages. C-reactive protein is a robust inflammatory biomarker and has clinical utility in the health surveillance of childhood cancer survivors.

    10. Radiation Oncology
      Socioeconomic factors affect the selection of proton radiation therapy for children

      Colette J. Shen, Chen Hu, Matthew M. Ladra, Amol K. Narang, Craig E. Pollack and Stephanie A. Terezakis

      Version of Record online: 27 JUN 2017 | DOI: 10.1002/cncr.30849

      • image
      • image
      • image

      Socioeconomic factors affect the use of proton radiotherapy in children. Whether this disparity is related to differences in the referral patterns, the knowledge of treatment modalities, or the ability to travel for therapy needs to be further clarified, but it is clear that improving access to proton therapy in underserved pediatric populations is essential.

    11. Disease Site

      Hematologic Malignancies
      Incidence of hematologic malignancy and cause-specific mortality in the Women's Health Initiative randomized controlled trial of calcium and vitamin D supplementation

      Eric M. Ammann, Matthew T. Drake, Bjarni Haraldsson, Robert B. Wallace, Karen C. Johnson, Pinkal Desai, Emily M. Lin and Brian K. Link

      Version of Record online: 27 JUN 2017 | DOI: 10.1002/cncr.30858

      • image
      • image
      • image
      • image
      • image

      In the Women's Health Initiative Calcium/Vitamin D trial, women assigned to calcium and vitamin D appear to have a significantly lower risk of incident hematologic malignancies over 10 years of follow-up. Although no significant association with hematologic cancer-specific mortality is noted, further research is needed to elucidate the possible role of vitamin D (and/or calcium) in the development and progression of hematologic malignancies.

    12. Discipline

      Disparities Research
      Impact of Medicaid disenrollment in Tennessee on breast cancer stage at diagnosis and treatment

      Wafa W. Tarazi, Cathy J. Bradley, Harry D. Bear, David W. Harless and Lindsay M. Sabik

      Version of Record online: 26 JUN 2017 | DOI: 10.1002/cncr.30771

      Medicaid disenrollment is associated with a later stage of disease at the time of breast cancer diagnosis. Policy makers need to consider the negative health impacts of Medicaid contractions when deciding on the future of Medicaid. See also pages 000-000.

  17. Editorial

    1. Delays in breast cancer diagnosis after a state policy limiting Medicaid enrollment

      Sujha Subramanian and Nancy L. Keating

      Version of Record online: 26 JUN 2017 | DOI: 10.1002/cncr.30769

      In this issue of Cancer, Tarazi et al investigate the effects of a state policy that substantially limited Medicaid enrollment on the timeliness of breast cancer diagnosis. They observe a statistically significant increase of 3.3 percentage points in the percentage of women diagnosed with late-stage disease after the policy change among women living in low-income versus high-income areas. See also pages 000-000.

  18. Original Articles

    1. Discipline

      Translational Research
      Global and targeted serum metabolic profiling of colorectal cancer progression

      Yin Long, Beatriz Sanchez-Espiridion, Moubin Lin, Lindsey White, Lopa Mishra, Gottumakkala S. Raju, Scott Kopetz, Cathy Eng, Michelle A. T. Hildebrandt, David W. Chang, Yuanqing Ye, Dong Liang and Xifeng Wu

      Version of Record online: 22 JUN 2017 | DOI: 10.1002/cncr.30829

      • image
      • image

      A multistage study involving global and targeted metabolic profiling of serum samples has been performed to identify biomarkers of progression to colorectal cancer. Decreased levels of xanthine and hypoxanthine and a high level of d-mannose correlate with increased colorectal adenoma polyp and colorectal cancer risk, and this suggests the potential utility of circulating metabolites in facilitating the screening and early detection of colorectal cancer.

    2. Medical Oncology
      The impact of cancer drug wastage on economic evaluations

      Judy Truong, Matthew C. Cheung, Helen Mai, Jessa Letargo, Alexandra Chambers, Mona Sabharwal, Maureen E. Trudeau and Kelvin K. W. Chan

      Version of Record online: 22 JUN 2017 | DOI: 10.1002/cncr.30807

      • image
      • image

      The wastage of anticancer drugs can have a significant impact on economic evaluation models according to this review of cost-effectiveness analyses submitted by drug manufacturers to the pan-Canadian Oncology Drug Review. The analysis shows that drug wastage increases incremental cost-effectiveness ratios in submitted analyses by a mean of 24%, 3-year total incremental costs by 26%, and total incremental drug budget costs by CaD $102 million nationally over a 3-year period. Guidance for consistent and informed modeling of drug wastage in economic evaluations is warranted. See also pages 000-000.

  19. Editorial

    1. Cancer drug wastage: The hidden cost in value-based cancer care delivery

      John M. Valgus

      Version of Record online: 22 JUN 2017 | DOI: 10.1002/cncr.30805

      Cancer drug wastage contributes significantly to overall cancer therapy costs. Strategies are needed to reduce cancer drug wastage. See also pages 000-000.

  20. Original Articles

    1. Discipline

      Outcomes Research
      Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation

      Lucy Hui, Gottfried von Keudell, Rong Wang, Amer M. Zeidan, Steven D. Gore, Xiaomei Ma, Amy J. Davidoff and Scott F. Huntington

      Version of Record online: 22 JUN 2017 | DOI: 10.1002/cncr.30818

      • image
      • image

      Brentuximab consolidation after transplantation for high-risk Hodgkin lymphoma is unlikely to be cost effective at current US prices. Indication-specific price reductions for the consolidative setting of approximately 20% would likely reduce incremental cost-effectiveness ratios to more widely acceptable values.

    2. Disparities Research
      You have full text access to this OnlineOpen article
      DNA mismatch repair deficiency and hereditary syndromes in Latino patients with colorectal cancer

      Charité N. Ricker, Diana L. Hanna, Cheng Peng, Nathalie T. Nguyen, Mariana C. Stern, Stephanie L. Schmit, Greg E. Idos, Ravi Patel, Steven Tsai, Veronica Ramirez, Sonia Lin, Vinay Shamasunadara, Afsaneh Barzi, Heinz-Josef Lenz and Jane C. Figueiredo

      Version of Record online: 22 JUN 2017 | DOI: 10.1002/cncr.30790

      • image

      The landscape of hereditary syndromes and clinicopathologic characteristics among Latino/Hispanic individuals in the United States with colorectal cancer remains poorly understood. Using data from the Hispanic Colorectal Cancer Study, approximately 13% of cases in the current study appear to have mismatch repair-deficient tumors, 61.9% of which will be confirmed to have Lynch syndrome.

    3. Clinical Trials
      Efficacy and safety of recombinant human lymphotoxin-α derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-label, controlled, phase 2b trial

      Feng-hua Wang, Yun Wang, Guo-ping Sun, Jian-hua Chen, Ying-cheng Lin, Wei Liu, Rong-sheng Zheng, Jia Chen, He-long Zhang, Hai-tao Lan, Jun Qi, Yang-qing Liu, Yan-ming Deng, Heng Zhao, Jian-ping Xiong, Qing Xu, Wen-qi Jiang and Yu-hong Li

      Version of Record online: 22 JUN 2017 | DOI: 10.1002/cncr.30845

      • image
      • image
      • image

      Combined recombinant human lymphotoxin-α derivative (rhLTα-Da) with cisplatin and fluorouracil failed to improve the progression-free survival and overall response rate in patients with metastatic esophageal squamous cell carcinoma, but only in a small subset with low levels of serum tumor necrosis factor receptor II. Derivatives that target membrane receptors only and eliminate the interference of serum receptors could be more promising for antitumor reconstructed lymphotoxin.

    4. Disease Site

      Breast Disease
      Decision-support networks of women newly diagnosed with breast cancer

      Lauren P. Wallner, Yun Li, M. Chandler McLeod, Ann S. Hamilton, Kevin C. Ward, Christine M. Veenstra, Lawrence C. An, Nancy K. Janz, Steven J. Katz and Sarah T. Hawley

      Version of Record online: 22 JUN 2017 | DOI: 10.1002/cncr.30848

      • image
      • image

      Women newly diagnosed with breast cancer turn to others, including spouses, children, and friends, to support them in their treatment decision making. These informal supporters are actively involved in the decision process, and involving more supporters is associated with more deliberative treatment decisions.

    5. Head and Neck Disease
      Treatment at high-volume facilities and academic centers is independently associated with improved survival in patients with locally advanced head and neck cancer

      John M. David, Allen S. Ho, Michael Luu, Emi J. Yoshida, Sungjin Kim, Alain C. Mita, Kevin S. Scher, Stephen L. Shiao, Mourad Tighiouart and Zachary S. Zumsteg

      Version of Record online: 22 JUN 2017 | DOI: 10.1002/cncr.30843

      • image
      • image
      • image

      For patients with locally advanced head and neck squamous cell carcinoma who are undergoing curative-intent radiotherapy, treatment at both high-volume facilities and academic centers is independently associated with improved survival. These findings were consistent when using a variety of thresholds to define high-volume facilities and across the vast majority of subgroups, including both oropharyngeal and nonoropharyngeal subsites.

    6. Discipline

      Clinical Trials
      A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma

      Stephen L. Chan, Winnie Yeo, Frankie Mo, Anthony W.H. Chan, Jane Koh, Leung Li, Edwin P. Hui, Charing C.N. Chong, Paul B.S Lai, Tony S.K. Mok and Simon C.H. Yu

      Version of Record online: 22 JUN 2017 | DOI: 10.1002/cncr.30825

      • image
      • image
      • image
      • image

      To the authors' knowledge, the current study is the first clinical trial regarding the combination of axitinib and transarterial chemoembolization in the treatment of patients with inoperable hepatocellular carcinoma. The results indicate that the combination is safe and provides an optimal outcome.

    7. Disease Site

      Gastrointestinal Disease
      RNA sequencing of esophageal adenocarcinomas identifies novel fusion transcripts, including NPC1-MELK, arising from a complex chromosomal rearrangement

      Zhixiong Wang, Yulan Cheng, John M. Abraham, Rong Yan, Xi Liu, Wei Chen, Sariat Ibrahim, Gary P. Schroth, Xiquan Ke, Yulong He and Stephen J. Meltzer

      Version of Record online: 22 JUN 2017 | DOI: 10.1002/cncr.30837

      • image
      • image
      • image

      The data in this study indicate that fusion transcripts occur at a stable frequency in esophageal adenocarcinoma. Furthermore, the results indicate that chromoplexy is an underlying mechanism generating fusion transcripts in esophageal adenocarcinoma.

    8. Discipline

      Outcomes Research
      Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study

      Amer M. Zeidan, Xin Hu, Jessica B. Long, Rong Wang, Xiaomei Ma, Nikolai A. Podoltsev, Scott F. Huntington, Steven D. Gore and Amy J. Davidoff

      Version of Record online: 16 JUN 2017 | DOI: 10.1002/cncr.30814

      • image
      • image
      • image
      • image
      • image

      Despite limited evidence, hypomethylating agents are commonly used to treat older patients with chronic myelomonocytic leukemia. This study demonstrates that the use of hypomethylating agents is associated with a 28% reduction in the risk of death in adjusted analyses. Improvements in supportive care do not solely account for temporal improvements in overall survival.

    9. Epidemiology
      Primary care visit use after positive fecal immunochemical test for colorectal cancer screening

      Grace Clarke Hillyer, Christopher D. Jensen, Wei K. Zhao, Alfred I. Neugut, Benjamin Lebwohl, Jasmin A. Tiro, Lawrence H. Kushi and Douglas A. Corley

      Version of Record online: 16 JUN 2017 | DOI: 10.1002/cncr.30809

      • image
      • image

      Positive cancer screening test results can be a stressful experience capable of influencing the use of health care services unrelated to medically indicated follow-up and, given the large size of screening outreach programs, have the potential to generate large numbers of primary care visits and substantial impacts on total health care costs. The results of the current study indicate that outpatient primary care use after fecal immunochemical test screening increased a small but significant amount for all major testing result groups and that changes in use take place in close temporal proximity to the screening test result.

    10. Radiation Oncology
      Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer

      Anna Torgeson, Shane Lloyd, Dustin Boothe, Randa Tao, Jonathan Whisenant, Ignacio Garrido-Laguna and George M. Cannon

      Version of Record online: 16 JUN 2017 | DOI: 10.1002/cncr.30780

      • image
      • image
      • image

      Patients with locally advanced, unresectable pancreatic cancer who undergo either chemoradiation or chemotherapy only are compared in the National Cancer Database. Multiagent chemotherapy followed by chemoradiation is associated with improved survival and pancreatectomy rates compared with chemotherapy alone and radiotherapy with concurrent chemotherapy.

  21. Commentary

    1. Hodgkin lymphoma classification: Are we at a crossroads?

      Antonino Carbone and Annunziata Gloghini

      Version of Record online: 16 JUN 2017 | DOI: 10.1002/cncr.30824

      • image

      On the basis of the putative origin from germinal center B cells, the gene expression profile, the expression of the B-cell phenotype, and the propensity to progress toward large B-cell lymphoma, nodular lymphocyte-predominant Hodgkin lymphoma should be classified as a special type of B-cell lymphoma with a follicular center cell origin. To guarantee the appropriate management of patients, information on the nodular growth patterns, the amount of (the number and the size) diffuse areas, and the tumor cell richness should be reported because of the clinical associations of these features.

  22. Correspondence

  23. Review Articles

    1. A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults

      Naval Daver, Kenneth McClain, Carl E. Allen, Sameer A. Parikh, Zaher Otrock, Cristhiam Rojas-Hernandez, Boris Blechacz, Sa Wang, Milen Minkov, Michael B. Jordan, Paul La Rosée and Hagop M. Kantarjian

      Version of Record online: 16 JUN 2017 | DOI: 10.1002/cncr.30826

      • image
      • image
      • image

      Malignancy-associated hemophagocytic lymphohistiocytosis (M-HLH) is a condition of growing proportions, especially with increased use of immune therapies, and is often missed or diagnosed late. This review focuses on improving awareness of M-HLH and discusses current and upcoming management strategies for M-HLH for community and academic oncologists.

  24. Original Articles

    1. Discipline

      Supportive Care
      The efficacy of Internet-based cognitive behavioral therapy for severely fatigued survivors of breast cancer compared with care as usual: A randomized controlled trial

      Harriët J.G. Abrahams, Marieke F.M. Gielissen, Rogier R.T. Donders, Martine M. Goedendorp, Agnes J. van der Wouw, Constans A.H.H.V.M. Verhagen and Hans Knoop

      Version of Record online: 16 JUN 2017 | DOI: 10.1002/cncr.30815

      • image
      • image

      The results of this randomized controlled trial indicate that Internet-based cognitive behavioral therapy is effective in reducing fatigue and related symptoms in survivors of breast cancer. This intervention meets the need for easily accessible and time-efficient interventions for individuals with cancer-related fatigue.

    2. Medical Oncology
      Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: A study report from the Spanish Lymphoma Oncology Group

      Mariano Provencio, Ana Royuela, María Torrente, Marina Pollán, José Gómez-Codina, Pilar Sabín, Marta Llanos, Josep Gumá, Cristina Quero, Ana Blasco, David Aguiar, Francisco Ramón García-Arroyo, Javier Lavernia, Natividad Martínez, Manuel Morales, Álvaro Saenz-Cusi, Delvys Rodríguez, Virginia Calvo, Luis de la Cruz-Merino, Miguel Ángel de la Cruz, Antonio Rueda and for the Spanish Lymphoma Oncology Group

      Version of Record online: 13 JUN 2017 | DOI: 10.1002/cncr.30795

      • image
      • image
      • image
      • image

      Relatively few studies have analyzed the mortality of follicular lymphoma patients in comparison with a sex- and age-matched general population. This study analyzes the overall survival of patients with follicular lymphoma and compares it with the expected survival of a general population. The long-term standardized mortality ratio, over the course of 10 years of follow-up, shows that patients with follicular lymphoma have a risk of dying similar to that of a sex- and age-matched general population.

    3. Association between patients' perception of the comorbidity burden and symptoms in outpatients with common solid tumors

      Christine S. Ritchie, Fengmin Zhao, Kanan Patel, Judith Manola, Elizabeth A. Kvale, Claire F. Snyder and Michael J. Fisch

      Version of Record online: 13 JUN 2017 | DOI: 10.1002/cncr.30801

      More than three-quarters of breast, lung, prostate, and colorectal cancer patients have comorbid conditions. Those with comorbidities have a greater symptom burden, and clinicians report more difficulty in managing patients' symptoms.

    4. Disease Site

      Chest and Lung Disease
      Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy

      Richard J. Cassidy, Xinyan Zhang, Pretesh R. Patel, Joseph W. Shelton, Chase E. Escott, Gabriel L. Sica, Michael R. Rossi, Charles E. Hill, Conor E. Steuer, Rathi N. Pillai, Suresh S. Ramalingam, Taofeek K. Owonikoko, Madhusmita Behera, Seth D. Force, Felix G. Fernandez, Walter J. Curran and Kristin A. Higgins

      Version of Record online: 13 JUN 2017 | DOI: 10.1002/cncr.30794

      • image
      • image

      To the authors' knowledge, no data exist regarding the prevalence of next-generation sequencing-detected mutations in patients with early-stage lung adenocarcinomas who are treated with stereotactic body radiotherapy. Herein, the authors report that the incidence of mutations and gene amplifications in patients with early-stage lung adenocarcinomas who are treated with stereotactic body radiotherapy is congruent with the advanced disease setting and that patients with KRAS-mutated tumors appear to have poorer local control and those with MET-amplified tumors have poorer regional and distant control.

VIEW

  1. 1 - 100
  2. 101 - 152

SEARCH

SEARCH BY CITATION